MaxCyte Announces Gram-Scale Antibody & Protein Production from the Transient Transfection of CHO Cells

Details Provided at the Phacilitate Forum in Washington, DC

GAITHERSBURG, Md.--(BUSINESS WIRE)--MaxCyte, Inc., the pioneer in scalable, high performance cell loading systems, announces the production of gram-scale quantities of proteins and antibodies from CHO cells using the MaxCyte® STX™ Scalable Transfection System. The MaxCyte STX has the capability to transfect from 5E5 to 1E10 cells with comparable results from small bench scale through screening and cGMP manufacturing. Recent results from MaxCyte STX users demonstrate the potential to achieve gram-scale antibody and protein production in an appropriate biomanufacturing host cell line with a simple 20-30 minute transfection run.

“We are delighted to announce the gram-scale antibody and protein yields achieved by users of the MaxCyte STX in standard biomanufacturing cell lines like CHO. Companies are no longer limited to settling for surrogate or non-relevant systems like HEK in order to generate enough protein or antibody for the development and screening of therapeutic biopharmaceuticals,” says Douglas Doerfler, President, and CEO of MaxCyte. “ By using the MaxCyte STX for cell transfection, companies now have the unprecedented capability to produce gram-scale quantities of antibodies and proteins in any appropriate manufacturing host background, including CHO, in less than two weeks, rather than the many months currently required for the development and re-development of non-relevant systems or stable cells lines.”

MaxCyte will be scheduling one-on-one consultations at the Phacilitate Protein Therapeutics Forum 2012 in Washington, DC, January 30-February 1. MaxCyte scientists will be present at their exhibition booth #17 to discuss how MaxCyte flow electroporation technology can improve the timelines and biological relevance of protein and antibody development.

About MaxCyte

MaxCyte specializes in cell modification technologies to enable the discovery, development, manufacturing, and delivery of innovative therapeutic products. Drawing on its cell therapy expertise, MaxCyte designed a portfolio of products including the MaxCyte® STX™ Scalable Transfection System and MaxCyte® VLX™ Large Scale Transfection System, ideal tools for use in drug discovery research and screening and protein production environments. These products provide for the rapid development and consistent production of billions of (co)transfected primary cells, stem cells, and cell lines for protein and antibody production and for cell-based assays with comparable results and Seamless Scalability™ from the bench to HTS and pilot scale.